AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10546697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg dose of recombinant leptin
Number of subjects: 127
Study 10546697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 10546697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg dose of recombinant leptin
Number of subjects: 127
Study 10546697 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of recombinant leptin
Number of subjects: 127
Study 10546697 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site reactions
Number of subjects: 127
Study 8932973 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote clinic monitoring and visual function tester certification via phone calls and centralized systems.
Number of subjects: 200
Study 8932973 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone certification of visual function technicians by regional coordinators.
Number of subjects: 200
Study 8932973 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly phone calls for clinic monitoring and annual patient exams.
Number of subjects: 200
Study 2009034 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 to 5 micrograms/kg per day)
Number of subjects: 47
Study 2009034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2009034 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 47
Study 7036334 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (average dose 2.6 mg daily)
Number of subjects: 78
Study 7036334 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa (average dose 750 mg daily)
Number of subjects: 78
Study 7036334 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 78
Study 7036334 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 78
Study 30978556 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aortic valve replacement
Number of subjects: 400
Study 30978556 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 400
Study 28063815 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4685
Study 28063815 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4685
Study 26365454 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention along with lifestyle modifications (listening to raga bhimpalas played on flute for 15min daily for at least 5 days/week for 3 months)
Number of subjects: 100
Study 26365454 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modifications only (according to Joint national committee VII guidelines)
Number of subjects: 100
Study 23578975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) treatment involving 3 periods of 5‐min occlusion at 220 mmHg
Number of subjects: 25
Study 23578975 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment involving 3 periods of 5‐min occlusion at 50 mmHg
Number of subjects: 25
Study 21896877 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava juice (300 mL containing ∼200 mg of ascorbic acid)
Number of subjects: 95
Study 21896877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (guava-flavored juice free of AA)
Number of subjects: 95
Study 19947275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined auricular point injection and superficial anesthesia (Group A)
Number of subjects: 40
Study 19947275 — intervention group
Group type: COMPARATOR
Intervention: Simple superficial anesthesia (Group B)
Number of subjects: 40
Study 17906168 — intervention group
Group type: COMPARATOR
Intervention: Experimental induction of good or bad news from research on aging (Study 1)
Number of subjects: 0
Study 17906168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in science (Study 2)
Number of subjects: 0
Study 17906168 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to control the 'when and how' of one's death
Number of subjects: 0
Study 15295946 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D plus E/HRT
Number of subjects: 49
Study 15295946 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D only
Number of subjects: 49
Study 11677705 — intervention group
Group type: EXPERIMENTAL
Intervention: In-practice educational session plus information pack (Group A)
Number of subjects: 426
Study 11677705 — intervention group
Group type: EXPERIMENTAL
Intervention: Information pack alone (Group B)
Number of subjects: 426
Study 11677705 — intervention group
Group type: COMPARATOR
Intervention: Neither educational session nor information pack (Group C - Control)
Number of subjects: 426
Study 11677705 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported confidence score (Group A)
Number of subjects: 426
Study 11677705 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported confidence score (Group B)
Number of subjects: 426
Study 11677705 — intervention group
Group type: COMPARATOR
Intervention: Reported confidence score (Group C - Control)
Number of subjects: 426
Study 9039200 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine 1% cream applied twice daily for 1 week
Number of subjects: 402
Study 9039200 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied twice daily for 1 week
Number of subjects: 402
Study 7705374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU d‐1)
Number of subjects: 55
Study 7705374 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g d‐1)
Number of subjects: 55
Study 7705374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium supplementation
Number of subjects: 55
Study 7705374 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 55
Study 3312033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 92
Study 3312033 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin/Tobramycin
Number of subjects: 92
Study 31246050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) followed by Imagery Rehearsal Therapy (IRT) and Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 100
Study 31246050 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) followed by supportive care therapy (SCT)
Number of subjects: 100
Study 31246050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) followed by IRT and CBT-I
Number of subjects: 100
Study 31206763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual strength training (LST), performed five times a week for 6 weeks, using tongue-to-palate resistance exercise method (isometric and isotonic exercise)
Number of subjects: 30
Study 31206763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 28045559 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobics exercise (45 minutes, 70%–75% HRmax)
Number of subjects: 50
Study 28045559 — intervention group
Group type: COMPARATOR
Intervention: Control session (no exercise for 45 minutes)
Number of subjects: 50
Study 26102252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilmapimod (10mg continuous infusion over 24 hours)
Number of subjects: 77
Study 26102252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 26102252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilmapimod (4-hour IV infusion)
Number of subjects: 77
Study 26102252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilmapimod (24-hour IV infusion)
Number of subjects: 77
Study 26102252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 77
Study 23384733 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (0.57 mg kg(‐1) h(‐1) for 1 h)
Number of subjects: 10
Study 23384733 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.065 mg kg(‐1) h(‐1) for 1 h)
Number of subjects: 10
Study 23384733 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 21904289 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 78
Study 21904289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 78
Study 21904289 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 78
Study 19460848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 27
Study 19460848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16456831 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (2, 2, and 1 mg/kg on days 1, 3, and 8 posttransplant)
Number of subjects: 30
Study 15156439 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg per day intravenous streptomycin, kanamycin, or amikacin
Number of subjects: 87
Study 15156439 — intervention group
Group type: COMPARATOR
Intervention: 25 mg/kg 3 times per week intravenous streptomycin, kanamycin, or amikacin
Number of subjects: 87
Study 11873034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 110
Study 11873034 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 110
Study 9755379 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 4000
Study 9755379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 7618049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical infusion of saline solution containing 10 microM capsaicin
Number of subjects: 21
Study 7618049 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group)
Number of subjects: 21
Study 2529295 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of alprazolam
Number of subjects: 81
Study 2529295 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of alprazolam
Number of subjects: 81
Study 2529295 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg of imipramine
Number of subjects: 81
Study 2529295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 401600 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (2 mg)
Number of subjects: 48
Study 401600 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline bromide (Pro-Banthine, 30 mg)
Number of subjects: 48
Study 401600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (solvent solution)
Number of subjects: 48
Study 31822353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided erector spinae plane block with 40ml of 0.25% bupivacaine
Number of subjects: 41
Study 31822353 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ultrasound-guided erector spinae plane block with 40ml of saline (Control)
Number of subjects: 41
Study 28282501 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite-impermeable bed encasings (active group)
Number of subjects: 284
Study 28282501 — intervention group
Group type: COMPARATOR
Intervention: Placebo bed encasings (control group)
Number of subjects: 284
Study 25497258 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted performance feedback reports (5 reports provided)
Number of subjects: 149
Study 25497258 — intervention group
Group type: COMPARATOR
Intervention: Standard performance feedback reports
Number of subjects: 149
Study 23295713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (thoracic epidural‐based analgesia)
Number of subjects: 26
Study 23295713 — intervention group
Group type: COMPARATOR
Intervention: Group P (systemic opioid‐based analgesia)
Number of subjects: 26
Study 20974645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially with seasonal virosomal-adjuvanted influenza vaccine
Number of subjects: 64
Study 20974645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered simultaneously with seasonal virosomal-adjuvanted influenza vaccine
Number of subjects: 64
Study 20974645 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal virosomal-adjuvanted influenza vaccine (administered sequentially or simultaneously)
Number of subjects: 64
Study 20974645 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of both vaccines
Number of subjects: 64
Study 20974645 — intervention group
Group type: COMPARATOR
Intervention: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially
Number of subjects: 64
Study 19493713 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1g, Metronidazole 500 mg b.i.d., Bismuth 240 mg b.i.d., Omeprazole 40 mg q.i.d. for 2 weeks
Number of subjects: 312
Study 19493713 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1g, Metronidazole 500 mg b.i.d., Bismuth 240 mg b.i.d., Omeprazole 40 mg q.i.d. plus 500 mg vitamin C per day for 2 weeks
Number of subjects: 312
Study 17251236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg
Number of subjects: 42
Study 17251236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 42
Study 17251236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17251236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 50 microg
Number of subjects: 42
Study 17251236 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 100 microg
Number of subjects: 42
Study 15139065 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thiotepa (750 mg/m2) and carboplatin (1600 mg/m2) with autologous stem cell transplantation (ASCT)
Number of subjects: 21
Study 15139065 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thiotepa and carboplatin with ASCT
Number of subjects: 21
Study 11059262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 13
Study 9374097 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel combination therapy, total doxorubicin dose limited to 360 mg/m2.
Number of subjects: 0
Study 1398238 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin EC 300 mg once daily for seven days before cholecystectomy
Number of subjects: 55
Study 1398238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 55
Study 1398238 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 55
Study 1398238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 4019551 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 60
Study 4019551 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate (Renografin‐76)
Number of subjects: 60
Study 31701623 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by pharmacist focusing on diet and exercise
Number of subjects: 118
Study 31701623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 118
Study 29651635 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (3 capsules totaling 9 × 10^13 colony-forming units per day of Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacteria longum)
Number of subjects: 21
Study 29651635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29375915 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Vagus Nerve Stimulation (VNS) with robotic rehabilitation
Number of subjects: 14
Study 29375915 — intervention group
Group type: COMPARATOR
Intervention: Sham Vagus Nerve Stimulation (VNS) with robotic rehabilitation
Number of subjects: 14
Study 25582875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CB-AdvA)
Number of subjects: 100
Study 25582875 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 100
Study 23915250 — intervention group
Group type: EXPERIMENTAL
Intervention: EBMeDS reminders
Number of subjects: 0
Study 23915250 — intervention group
Group type: COMPARATOR
Intervention: Usual care process
Number of subjects: 0
Study 21921743 — intervention group
Group type: COMPARATOR
Intervention: Pressure garment therapy alone
Number of subjects: 43
Study 21921743 — intervention group
Group type: COMPARATOR
Intervention: Silicone spray and compression
Number of subjects: 43
Study 21921743 — intervention group
Group type: COMPARATOR
Intervention: Silicone sheeting and compression
Number of subjects: 43
Study 21921743 — intervention group
Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 43
Study 19810584 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-nidra with oral hypoglycaemic
Number of subjects: 41
Study 19810584 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycaemic alone
Number of subjects: 41
Study 16759045 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg Z-100
Number of subjects: 32
Study 16759045 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg Z-100
Number of subjects: 32
Study 16759045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 14715189 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide (Per/Ind)
Number of subjects: 0
Study 14715189 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 11513913 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous bolus injection of ACTH-(1-24)
Number of subjects: 0
Study 11513913 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 9028722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 25 micrograms/h
Number of subjects: 8
Study 9028722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8383517 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (beta 2-adrenoceptor agonist)
Number of subjects: 10
Study 8383517 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (partial beta 1-agonist)
Number of subjects: 10
Study 8383517 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 10
Study 3948048 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (50 micrograms . kg‐1)
Number of subjects: 64
Study 3948048 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (7.5 micrograms . kg‐1)
Number of subjects: 64
Study 3948048 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms . kg‐1)
Number of subjects: 64
Study 3948048 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for droperidol)
Number of subjects: 64
Study 3232105 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish applied to air dried surfaces for 6 hours
Number of subjects: 30
Study 3232105 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish applied to water-wetted surfaces for 6 hours
Number of subjects: 30
Study 3232105 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish applied to saliva-wetted surfaces for 6 hours
Number of subjects: 30
Study 31929465 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes Toward Mood Stabilizers Questionnaire (AMSQ)
Number of subjects: 0
Study 31929465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets Routine Questionnaire (TRQ)
Number of subjects: 0
Study 31216949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day preoperative protein-calorie restriction regimen (30% calorie/70% protein restriction)
Number of subjects: 4
Study 31216949 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum group
Number of subjects: 4
Study 26914856 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured transfer training intervention
Number of subjects: 0
Study 26914856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 26914856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 25963380 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C (2000 mg) with air breathing
Number of subjects: 10
Study 25963380 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 40% O2 breathing
Number of subjects: 10
Study 25963380 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C (2000 mg) with 40% O2 breathing
Number of subjects: 10
Study 23053702 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth 811 sealer (Group 1)
Number of subjects: 80
Study 23053702 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26 (Group 2)
Number of subjects: 80
Study 23053702 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow (Group 3)
Number of subjects: 80
Study 23053702 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany SE (Group 4)
Number of subjects: 80
Study 23053702 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 5)
Number of subjects: 80
Study 21654701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (control +102 g oat bran/day)
Number of subjects: 24
Study 21654701 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fiber diet)
Number of subjects: 24
Study 18053054 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound care with 500 mg of levofloxacin by mouth daily
Number of subjects: 82
Study 18053054 — intervention group
Group type: COMPARATOR
Intervention: Local wound care alone
Number of subjects: 82
Study 16512787 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering (decrease in SBP from 141±11 mmHg to 133±12 mmHg)
Number of subjects: 48
Study 16512787 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycaemic control (reduced HbA(1c) after 12 months)
Number of subjects: 48
Study 16512787 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in left ventricular mass
Number of subjects: 48
Study 12915396 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal containing [3H]triolein consumed by patients before surgery
Number of subjects: 20
Study 12915396 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal containing [3H]triolein consumed by normal, healthy volunteers
Number of subjects: 20
Study 12915396 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental fat as a surrogate for visceral fat
Number of subjects: 20
Study 12915396 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous fat depots
Number of subjects: 20
Study 11053705 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 150
Study 11053705 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 150